▎WuXi AppTec Content Team Report

Recently, Argo Biopharma (hereinafter referred to as "Argo") announced that its self-developedThe First Cardiovascular siRNA DrugBW-01, alreadyCompleted in January this yearPhase 1 clinical trials conducted in Australia and Phase 1 clinical trials in China have achieved positive results.

The test data shows,BW-01 demonstrated good safety and tolerability profiles in both trials., no deaths or adverse events leading to discontinuation or withdrawal from the study occurred, and no serious adverse events were reported in the active drug group.Single-dose subcutaneous injection shows significant improvement in pharmacodynamic indicators for up to 24 weeks.Argo Biopharma plans to launch the phase 2 clinical trial of BW-01 in the first half of this year.

siRNA Drugs (Small Interfering Nucleic Acid Drugs) are an emerging technology that has gained prominence in recent years. They boast numerous druggable targets, strong efficacy, good safety, low dosing frequency, and a wide range of indications, including cardiovascular diseases, rare diseases, neurological disorders, viral hepatitis, ophthalmic diseases, and cancer, making them one of the most promising frontier areas in the global pharmaceutical industry.

Argo Biopharma, established in 2021, is a clinical-stage biotechnology company dedicated to developing the next generation of siRNA drugs to provide better treatment options for patients worldwide. In less than three years, Argo Biopharma has built a rich and differentiated pipeline of siRNA drug candidates covering a wide range of indications. Currently, the company has five siRNA drugs that have entered Phase 1 clinical trials. In November 2023, the company also announcedCompleted 300 million RMBA+ RoundFinancing,This round of financing was led bySDIC Capital Leads Investment，Huagai Capital, Yuanxi Haihe Fund, and existing shareholder Sanyi Innovation Investment followed up on the investment.。

It is worth mentioning that, in January 2024,Argo Biopharma Announces Multiple RNAi Project Licenses and Strategic Collaboration with NovartisAccording to the agreement, Argo Biopharma will receive an upfront payment of $185 million from Novartis, as well as milestone payments with a total potential transaction value of nearly $4.2 billion and tiered royalties on commercial sales.

Focusing on the Frontier, Brilliant Stars! During the JPM Conference in San Francisco"2024 Wuxi AppTec Global Forum"On site, thousands of industry professionals gathered, and more than 30 industry leaders shared exclusive insights. To enable more colleagues in the industry to watch the exciting content across time and space,From 10:00 to 14:30 Beijing Time on February 1, we will provide a limited-time free online replay of the "2024 WuXi AppTec Global Forum."。

Why are industry leaders optimistic about 2024? What insights does the GLP-1 agonist boom offer us? In the field of cancer and broader disease areas, how will emerging therapies reshape the treatment landscape? Which technologies and directions might see a breakthrough in the new year?Welcome to scan the QR code at the end to view the full agenda and register for scheduled viewing.！

▲This forum is freely open to a global audience. Press and hold to scan the QR code above to apply for viewing.